New Drug Application for Bayer’s FXIa Inhibitor Asundexian Accepted by U.S. Food and Drug Administration Under Priority Review

Дата публикации: 19-05-2026 23:05:28

Berlin, May 19, 2026 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDA) for its investigational Factor XIa (FXIa) inhibitor, asundexian, for the prevention of...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
2	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
3	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
4	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST	0	10.76	28-05-2026
5	Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA	0	10.06	17-07-2026
6	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
7	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	0	8.22	01-06-2026
8	Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer	0	14.56	22-07-2026
9	Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)	0	17.8	26-05-2026
10	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.56. Источник: www.drugs.com.